Nogra Pharma Ltd.

Celgene Corp. and Acceleron Pharma Inc. anticipate first half 2019 global regulatory filings for luspatercept based on Phase III results in myelodysplastic syndromes (MDS), giving Celgene a much-ne

Celgene Corp. told investors almost exactly what they needed to hear during its earnings report on May 4 – that the company's first quarter revenue exceeded expectations enough to boost full-year gui

Celgene Corp. has invested billions of dollars in its inflammation and immunology (I&I) franchise through internal development as well as partnered programs and acquisitions, so a few setbacks on the

Celgene Corp. revealed more bad news it didn't need on Feb. 27 when the company said it received a refuse-to-file letter from the US FDA for the new drug application (NDA) for ozanimod in multiple s